|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008972,
umls-concept:C0023911,
umls-concept:C0023981,
umls-concept:C0030705,
umls-concept:C0034656,
umls-concept:C0205195,
umls-concept:C0205390,
umls-concept:C0723595,
umls-concept:C0796679,
umls-concept:C1412186,
umls-concept:C1516119,
umls-concept:C1696465,
umls-concept:C2239176
|
|
pubmed:dateCreated |
2009-1-26
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
Disease progression of hepatocellular cancer (HCC) in patients eligible for liver transplantation (LTx) occurs in up to 50% of patients, resulting in withdrawal from the LTx waiting list. Transarterial chemoembolization (TACE) is used as bridging therapy with highly variable response rates. The oral multikinase inhibitor sorafenib significantly increases overall survival and time-to-progression in patients with advanced hepatocellular cancer.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-10072408,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-12540794,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-12783395,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-15004776,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-15519517,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-15760403,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-15760404,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-15973710,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-16315294,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-16482577,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-18650514,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-2990661,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-7708069,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-8433390,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-8594428,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-9409568,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-9620330,
http://linkedlifedata.com/resource/pubmed/commentcorrection/19036146-9696501
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
1471-2407
|
|
pubmed:author |
pubmed-author:BüchlerM WMW,
pubmed-author:HOUSEB JBJ,
pubmed-author:HeiningCC,
pubmed-author:HoffmannKK,
pubmed-author:JaegerDD,
pubmed-author:RadeleffBB,
pubmed-author:RichterGG,
pubmed-author:SchemmerPP,
pubmed-author:SchenkerOO,
pubmed-author:SchirrmacherPP,
pubmed-author:SchmidtJJ,
pubmed-author:Zahlten-HinguranageAA,
pubmed-author:von KalleCC
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
8
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
349
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:19036146-Adult,
pubmed-meshheading:19036146-Antineoplastic Agents,
pubmed-meshheading:19036146-Benzenesulfonates,
pubmed-meshheading:19036146-Carcinoma, Hepatocellular,
pubmed-meshheading:19036146-Chemoembolization, Therapeutic,
pubmed-meshheading:19036146-Combined Modality Therapy,
pubmed-meshheading:19036146-Double-Blind Method,
pubmed-meshheading:19036146-Female,
pubmed-meshheading:19036146-Humans,
pubmed-meshheading:19036146-Liver Neoplasms,
pubmed-meshheading:19036146-Liver Transplantation,
pubmed-meshheading:19036146-Male,
pubmed-meshheading:19036146-Pyridines,
pubmed-meshheading:19036146-Research Design
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
|
|
pubmed:affiliation |
Department of Surgery, Ruprecht-Karls-University, Heidelberg, Germany. Katrin.Hoffmann@med.uni-heidelberg.de
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
